Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher S Hourigan

Showing results (11-20 of 145) with videos related to

Pageof 15
Sort By:
Blood Advances|September 12, 2025
Overall survival, conditioning, and MRD in MORPHOGege Gui, Christopher S Hourigan
Current Drug Targets|February 24, 2015
Novel Antigen Targets for Immunotherapy of Acute Myeloid LeukemiaMeghali Goswami, Christopher S Hourigan
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Development of therapeutic agents for older patients with acute myelogenous leukemiaChristopher S Hourigan, Judith E Karp
Nature Reviews. Clinical Oncology|June 27, 2013
Minimal residual disease in acute myeloid leukaemiaChristopher S Hourigan, Judith E Karp
Hematology. American Society of Hematology. Education Program|December 7, 2019
MRD evaluation of AML in clinical practice: are we there yet?Sylvie D Freeman, Christopher S Hourigan
Clinical Investigation|March 6, 2013
New considerations in the design of clinical trials for the treatment of acute leukemiaChristopher S Hourigan, Judith E Karp
Cancer Discovery|October 5, 2016
Accurate Medicine: Indirect Targeting of NPM1-Mutated AMLChristopher S Hourigan, Peter D Aplan
Cancer Journal (Sudbury, Mass.)|September 29, 2011
Evaluation of current cancer immunotherapy: hemato-oncologyChristopher S Hourigan, Hyam I Levitsky
Acta Haematologica|November 30, 2023
Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid LeukemiaAmanda L Blackmon, Christopher S Hourigan
The Lancet. Haematology|July 21, 2018
Leukaemia risk associated with low-dose radiationChristopher S Hourigan, Bipin N Savani
Pageof 15

Showing results (11-20 of 145) with videos related to

Sort By:
Pageof 15
Blood Advances|September 12, 2025
Overall survival, conditioning, and MRD in MORPHOGege Gui, Christopher S Hourigan
Current Drug Targets|February 24, 2015
Novel Antigen Targets for Immunotherapy of Acute Myeloid LeukemiaMeghali Goswami, Christopher S Hourigan
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Development of therapeutic agents for older patients with acute myelogenous leukemiaChristopher S Hourigan, Judith E Karp
Nature Reviews. Clinical Oncology|June 27, 2013
Minimal residual disease in acute myeloid leukaemiaChristopher S Hourigan, Judith E Karp
Hematology. American Society of Hematology. Education Program|December 7, 2019
MRD evaluation of AML in clinical practice: are we there yet?Sylvie D Freeman, Christopher S Hourigan
Clinical Investigation|March 6, 2013
New considerations in the design of clinical trials for the treatment of acute leukemiaChristopher S Hourigan, Judith E Karp
Cancer Discovery|October 5, 2016
Accurate Medicine: Indirect Targeting of NPM1-Mutated AMLChristopher S Hourigan, Peter D Aplan
Cancer Journal (Sudbury, Mass.)|September 29, 2011
Evaluation of current cancer immunotherapy: hemato-oncologyChristopher S Hourigan, Hyam I Levitsky
Acta Haematologica|November 30, 2023
Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid LeukemiaAmanda L Blackmon, Christopher S Hourigan
The Lancet. Haematology|July 21, 2018
Leukaemia risk associated with low-dose radiationChristopher S Hourigan, Bipin N Savani
Pageof 15